Site Search
Displaying results 61 - 64 of 64
Resource | Publications,
Oral PrEP is an additional HIV prevention option for individuals at substantial risk of HIV exposure that will be effective as part of a comprehensive response to HIV.
The World Health Organization (WHO) anticipates releasing updated guidance on oral pre-exposure prophylaxis (PrEP), containing tenofovir (TDF), as an additional HIV prevention choice. The new guidance is likely to be significantly broader than previously and creates real opportunities to move forward with implementing PrEP as part of comprehensive HIV programmes. This publication, produced collaboratively between UNAIDS, WHO and AVAC, is intended to complement WHO recommendations and support the optimal use of oral PrEP to protect individuals and contribute to ending the AIDS epidemic.
Resource | Publications,
The WHO HIV Department began its work on PrEP in 2009 to help countries prepare for potential implementation of PrEP, should the trials show sufficient safety and effectiveness. With its partner UNAIDS, and in partnership with Georgetown University School of Law, WHO convened a number of country and regional consultations to address issues of PrEP implementation and to help countries think through the process and the implications.
Resource | Publications,
APCOM’s Highlight series profile the often unheard of MSM and transgender community- based documentation of good practices from projects across Asia and the Pacific.
APCOM works with individuals and organisations on the Highlight series to form the evidence- based information to be shared across the region and for advocacy on issues that affect the lives of MSM and transgender people, including HIV, rights, health and well being.
This case study focus on using the internet for mass mobilisation of the MSM community for the purpose of HIV testing.
Resource | Guidelines,
Clinical trials on PrEP began in 2005. These trials have focused on the effectiveness of PrEP among people who inject drugs, HIV serodiscordant couples, heterosexual men and women, women at higher risk of HIV exposure, and men and transgender women who have sex with men (MSM-TG). Of these, two have completed as planned, one was stopped early for effectiveness, and two others were stopped or had arms discontinued for reasons of futility.